Cite
HARVARD Citation
Hata, A. et al. (2022). Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. Journal of clinical oncology. 40 (2), pp. 180-188. [Online].